Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8784MR)

This product GTTS-WQ8784MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Hypercholesterolemia research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ8784MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14483MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RYI-018
GTTS-WQ8425MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ5240MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CB 2679d
GTTS-WQ11217MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ9344MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ7397MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GA101
GTTS-WQ11686MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ9080MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMC-A12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW